Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0837 GMT – Bayer’s positive results for the asundexian medication for stroke-risk reduction in its recent clinical trial is a good thing for the company, JP Morgan analysts say in a note. Despite this, the analysts say that detailed results and competitor data will be more telling about its role in the secondary stroke market—referring to treatment for a second stroke after a patient has already experienced a first one—. The analysts say they previously forecast the Secondary Stroke market at around 3 billion euros. Meanwhile, the drug’s lack of increase in the risk of major bleeding is favourable too, the analysts say. Shares are up 9.8% at 30.30 euros per share. (aimee.look@wsj.com)